FBTAX Performance — Fidelity Advisor Biotechnology Fund, Class A
Data updated: 2026-10-13
FBTAX returned +20.61% year to date and +62.24% over one year to Jul 2026. Over one year the fund beat its Health Care Equity category average: $100 grew to $162, against $137 for the category. Volatility over the past 12 months was 21.05% a year. In the 12 months to Jul 2026 the fund lost a net $22.5M, and assets reached $2.20B.
FBTAX Growth of $100
What $100 invested in Fidelity Advisor Biotechnology Fund grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | FBTAX | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $162 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $63 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $14 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $5 | $183 |
FBTAX Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +20.61% |
| 1 year | +62.24% |
3- and 5-year figures withheld: returns differ from sibling classes.
FBTAX Annual Returns
Calendar-year total returns of Fidelity Advisor Biotechnology Fund, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +20.61% |
| 2025 | +23.94% |
| 2024 | −48.25% |
| 2023 | −45.61% |
| 2022 | −54.76% |
| 2021 | −52.65% |
| 2020 | −35.14% |
| 2019 (Aug–Dec) | −13.41% |
FBTAX Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +1.4% | +2.2% | −1.3% | +2.1% | +0.5% | +15.8% | −0.7% | — | — | — | — | — |
| 2025 | −4.9% | −6.3% | −5.2% | +0.6% | −3.2% | +3.6% | +8.1% | +5.9% | +10.9% | +8.6% | +10.6% | −4.7% |
| 2024 | −1.8% | +0.4% | −3.9% | −14.2% | −4.1% | −1.5% | +1.7% | −2.9% | −5.3% | −5.3% | −11.6% | −13.9% |
| 2023 | −4.7% | −9.1% | −7.9% | −2.7% | −5.5% | −5.3% | −3.7% | −8.5% | −9.6% | −11.1% | −1.8% | +12.6% |
| 2022 | −17.8% | −5.5% | −1.2% | −18.1% | −11.5% | −0.5% | −3.2% | +2.2% | −7.6% | −0.6% | −4.2% | −6.0% |
| 2021 | −5.2% | −5.2% | −10.2% | −4.5% | −10.3% | −0.5% | −7.5% | +2.4% | −10.5% | −4.6% | −11.7% | −3.6% |
| 2020 | −10.7% | −5.4% | −12.3% | +8.2% | +4.7% | −3.6% | −8.9% | −4.0% | −4.6% | −7.5% | +6.1% | −1.9% |
| 2019 | — | — | — | — | — | — | — | −7.4% | −8.6% | +0.5% | +5.1% | −3.0% |
FBTAX Risk
Risk measures from monthly returns over Aug 2025 – Jul 2026.
- 1-year volatility (annualised): 21.05%
- Best month: +15.81% (Jun 2026)
- Worst month: −4.66% (Dec 2025)
FBTAX Fund Flows
Monthly money in and out of Fidelity Advisor Biotechnology Fund, from SEC Form N-PORT.
- 12-month net flow: −$22.5M
- 12-month gross sales (incl. reinvestments): $320.8M
- Sales ÷ redemptions: 0.93×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $42.1M | $28.9M | $13.2M |
| Jun 2026 | $27.9M | $27.8M | $95K |
| May 2026 | $16.4M | $28.0M | −$11.6M |
| Apr 2026 | $18.8M | $25.9M | −$7.0M |
| Mar 2026 | $19.0M | $24.8M | −$5.8M |
| Feb 2026 | $25.7M | $29.6M | −$4.0M |
| Jan 2026 | $24.4M | $27.8M | −$3.4M |
| Dec 2025 | $53.3M | $27.5M | $25.8M |
| Nov 2025 | $33.2M | $26.7M | $6.5M |
| Oct 2025 | $25.9M | $31.1M | −$5.2M |
| Sep 2025 | $16.4M | $28.1M | −$11.6M |
| Aug 2025 | $17.6M | $37.0M | −$19.4M |
FBTAX Assets Under Management
Net assets of Fidelity Advisor Biotechnology Fund by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $2.20B |
| 2026-04-30 | $1.90B |
| 2026-01-31 | $1.87B |
| 2025-10-31 | $1.74B |
| 2025-07-31 | $1.40B |
| 2025-04-30 | $1.37B |
| 2025-01-31 | $1.54B |
| 2024-10-31 | $1.88B |
| 2024-07-31 | $1.81B |
| 2024-04-30 | $1.63B |
| 2024-01-31 | $1.68B |
| 2023-10-31 | $1.36B |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.